ClinicalTrials.gg
RecruitingNCT07290270PSMArealUpdated Mar 30, 2026

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

An observational study in Metastatic Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in China. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
18 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Started
2026
with 5 others
Observational
9 of 82
5 open now
Primary completion
2029-08
later than 18 of 24 live
Registered
75th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is one of 6 that started in 2026, is one of 9 observational ones, reaches primary completion later than 18 of the 24 other live ones, and was the 75th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

This non-interventional, observational, multicenter, prospective cohort study is designed to investigate the treatment patterns of mPC patients treated with lutetium (177Lu) vipivotide tetraxetan, as well as their clinical outcomes, real-world characteristics, and quality of life during the treatment period and up to one year after treatment completion.

Read the detailed description

The study population will be divided into two cohorts, enrolling patients with mCRPC and mHSPC, respectively. Patients planned to receive lutetium (177Lu) vipivotide tetraxetan treatment according to treating physician's assessment will be enrolled in the study upon signing an informed consent form. Patients must meet all inclusion criteria defined in the protocol and not meet any exclusion criteria. The patients' medical history, prostate cancer disease characteristics, demographics, and baseline data will be collected through medical records and examination reports. Treatment patterns, treatment outcomes, and HRQoL data will be collected during study follow-up visits through patient records, examination reports, and self-reported data. This study does not have a control group; instead, a self-control method will be used, with the patients' baseline data before the start of treatment serving as the control for efficacy, safety, and HRQoL assessments. The index date for this study is defined as the date of the first administration of lutetium (177Lu) vipivotide tetraxetan

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Metastatic Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Hormone-Sensitive Prostate Cancer
  • Lutetium (177Lu) vipivotide tetraxetan Injection
  • Non-interventional Study
  • China
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will be recruited from approximately 25 research centers in China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult male patients diagnosed with mCRPC or mHSPC Initiating lutetium (177Lu) vipivotide tetraxetan treatment by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of cycle 1 Written ICF must be obtained prior to any data collection Participants must have adequate organ function following Society of Nuclear Medicine and Molecular Imaging (SNMMI) consensus (Hope et al., 2023)

Exclusion criteria

Exclusion Criteria:

Simultaneous participation in any trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan during the study period

Other protocol-defined inclusion / exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Patients diagnosed with Metastatic Castration-Resistant Prostate Cancer (mCRPC) previously treated with at least one ARPI with or without taxane regimens.

  • Cohort 2

    Patients diagnosed with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

06

What researchers measure

Primary outcomes

  1. prostate-specific antigen (PSA) 50 response rate

    Defined as the proportion of patients with a confirmed decrease in PSA levels by ≥50% from baseline

    Time frame: from 1 month before the index date through to 1 year after the end-of-treatment (EOT) visit

  2. prostate-specific antigen (PSA) 90 response rate

    Defined as the proportion of patients with confirmed decreases in PSA level by ≥90% from baseline

    Time frame: from 1 month before the index date through to 1 year after the end-of-treatment (EOT) visit

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from the index date to the first occurrence of PSA progression or radiographic progression according to the Prostate Cancer Working Group 3 criteria, clinical progression assessed by the investigator, or death due to any cause (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  2. Radiographic progression-free survival (rPFS)

    Defined as the time from the index date to the first occurrence of radiographic progression according to the PCWG3 criteria or death due to any cause (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  3. Clinical PFS

    Defined as the time from the index date to the first occurrence of clinical progression assessed by the investigator or death due to any cause (whichever occurs first). Clinical progression is determined by the investigator and may be based on the following criteria: 1) Significant increase in tumor pain requiring initiation of another systemic anti-cancer treatment regimen; 2) The need to immediately start new anti-cancer treatment, surgery, or radiotherapy intervention due to complications caused by tumor progression, even in the absence of radiographic progression; 3) Deterioration of Eastern Cooperative Oncology Group (ECOG) performance status to ≥ 3, and the investigator determines that the deterioration indicates clinical progression

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  4. Time to PSA progression

    Defined as the time from the index date to the first occurrence of PSA progression or death due to any cause. According to the PCWG3 criteria, PSA progression is defined as follows: 1. For patients whose PSA has declined from baseline: PSA increased by ≥25% compared with the lowest value and the absolute value was ≥2 ng/mL, and was re-evaluated and confirmed after ≥3 weeks. 2. For patients whose PSA has not declined from baseline: After at least 12 weeks of treatment with the study drug, the PSA level increased by ≥25% from the baseline and the absolute value was ≥2 ng/mL

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  5. Second Progression-Free Survival (PFS2)

    Defined as the time from the initiation of the first subsequent systemic anti-tumor therapy following the end of treatment with lutetium (177Lu) vipivotide tetraxetan to the first occurrence of radiographic progression or PSA progression according to the PCWG3 criteria, clinical progression as assessed by the investigator, or death due to any cause (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  6. OS

    Defined as the time from the index date to death due to any cause

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  7. Time to a first symptomatic skeletal event (SSE)

    Defined as the time from the index date to the first occurrence of an SSE. SSEs include the use of external beam radiation therapy to prevent or palliate skeletal symptoms, the occurrence of a new symptomatic pathological fracture (vertebral or non-vertebral), the occurrence of spinal cord compression, or tumor-related orthopedic surgical intervention (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  8. Time to first subsequent therapy

    Defined as the time from the index date to the start date of the first subsequent therapy for prostate cancer. Subsequent therapy refers to systemic anti-tumor treatment initiated after the patient discontinues lutetium (177Lu) vipivotide tetraxetan treatment

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  9. Disease control rate (DCR)

    Defined as the proportion of patients with complete response (CR) / partial response (PR), and stable disease (SD) as the best response in soft tissue lesion evaluation

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  10. Objective response rate (ORR)

    Defined as the proportion of patients with CR and PR as the best response in soft tissue lesion evaluation assessed referring to the evaluation criteria

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  11. Time to response (TTR)

    Defined as the time from the index date to the first documentation of CR or PR for soft tissue lesions referring to the evaluation criteria

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  12. Duration of response (DoR)

    Defined as the time from the first documentation of objective response (CR or PR) to the first occurrence of disease progression (radiographic, clinical, or PSA progression) or death due to any cause (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  13. Time to soft tissue progression (TTSTP)

    Defined as the time from the index date to the occurrence of soft tissue progression referring to the evaluation criteria or death due to any cause (whichever occurs first)

    Time frame: Data collection for radiographic assessment outcomes: from 3 months before the index date to 1 year after the EOT visit / Data collection for non-radiographic assessment outcomes: from 1 month before the index date to 1 year after the EOT visit

  14. Number of participants by treatment dose and cycles of lutetium (177Lu) vipivotide tetraxetan

    Number of participants by treatment dose and cycles of lutetium (177Lu) vipivotide tetraxetan

    Time frame: Data collection of previous treatments for prostate cancer: from the time of prostate cancer diagnosis to the index date / Data collection of subsequent treatments for prostate cancer: from the index date to 1 year after the EOT visit

  15. Number of participants by treatment sequences for prostate cancer

    Prior treatment lines and subsequent treatments (including: ARPI, ADT, chemotherapy, radical prostatectomy, radiological treatment etc.)

    Time frame: Data collection of previous treatments for prostate cancer: from the time of prostate cancer diagnosis to the index date / Data collection of subsequent treatments for prostate cancer: from the index date to 1 year after the EOT visit

  16. Patient demographics and baseline characteristics

    Time frame: From 1 month before the index date to the index date

  17. Prostate cancer disease characteristics: Number of patients with Previous prostate cancer history

    Time frame: Baseline

  18. Prostate cancer disease characteristics: Gleason score

    Typical Gleason Scores range from 6-10. The higher the Gleason Score, the more likely that the cancer will grow and spread quickly.

    Time frame: From 1 month before the index date to the index date

  19. Prostate cancer disease characteristics: Number of patients by metastasis status

    Time frame: From 1 month before the index date to the index date

  20. Prostate cancer disease characteristics: Number of patients by prostate cancer-related genetic mutation status

    Time frame: From 1 month before the index date to the index date

  21. Prostate cancer disease characteristics: Baseline prostate-specific antigen (PSA) level

    Time frame: Baseline

  22. Prostate cancer disease characteristics: prostate-specific antigen (PSA) doubling time

    Time frame: From 1 month before the index date to the index date

  23. Prostate cancer disease characteristics: Prostate-Specific Membrane Antigen (PSMA) diagnostic drug usage

    Time frame: From 1 month before the index date to the index date

  24. Prostate cancer disease characteristics: Baseline PET-CT results

    Time frame: Baseline

  25. Prostate cancer disease characteristics: Baseline testosterone level

    Time frame: Baseline

  26. Prostate cancer disease characteristics: Baseline Eastern Cooperative Oncology Group (ECOG) performance status

    ECOG performance status is measured on a 6 point grade scale. 0: Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead.

    Time frame: Baseline

  27. Prostate cancer disease characteristics: Number of patients with family history of prostate cancer

    Time frame: Baseline

  28. Prostate cancer disease characteristics: Number of patients with carcinoembryonic Antigen (CEA)

    Time frame: From 1 month before the index date to the index date

  29. Adverse events

    Time frame: From the index date to 1 year after the EOT visit

  30. FACT-P score

    The FACT-P was developed to measure the health-related quality of life (HRQOL) in patients diagnosed with prostate cancer. It extends the general FACT-G scale, which assesses cancer patients' overall quality of life, by adding specific items related to prostate cancer therapy. The FACT-P consists of two main sections: 1. FACT-G: A general section that covers four domains: Physical Well-Being (PWB),Social/Family Well-Being (SWB),Emotional Well-Being (EWB),Functional Well-Being (FWB) 2. Prostate Cancer Specific Section: Focuses on issues unique to prostate cancer patients, such as urinary symptoms, sexual health, and the side effects of treatment. The scoring system for the FACT-P uses a 5-point Likert scale (from 0 to 4,from good to bad). Scores are calculated across different domains and subscales, and the total score is calculated by summing the scores across all domains, providing a range of 0 to 156. A high FACT-P score indicates a worse outcome.

    Time frame: From 1 month before the index date to 1 year after the EOT visit

  31. BPI-SF score

    Brief Pain Inventory-Short Form (BPI-SF). The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. BPI assessment areas including severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week. No scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference.

    Time frame: From 1 month before the index date to 1 year after the EOT visit

  32. EQ-5D-5L questionnaire score

    EuroQol 5-Dimension 5-Level (EQ-5D-5L). The 5-level EQ-5D version (EQ-5D-5L) descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: From 1 month before the index date to 1 year after the EOT visit

  33. FACT-RNT score

    Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT). The FACT-RNT was designed for use and future adaptation with a broad variety of RNT agents with different molecular targeting mechanisms and radioisotopes. The FACT-RNT, a 15-item measure of symptoms/toxicities with higher total scores(range:0-60) indicating less symptom burden.

    Time frame: From 1 month before the index date to 1 year after the EOT visit

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Shanghai, Shanghai Municipality China, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 42 months is close to that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 18, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290270
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Feb 4, 2026
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Mar 30, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion